PCM
IBER

Prelude Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Prelude Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$98K – 2201
2022
Q1 		$98K Hold
10,000
– – ﹤0.01% 1422
2021
Q4 		$97K Sell
10,000
-3,634
-27% -$35.3K ﹤0.01% 1732
2021
Q3 		$133K Buy
13,634
+3,634
+36% +$35.1K ﹤0.01% 1457
2021
Q2 		$97K Buy
+10,000
New +$97.3K ﹤0.01% 1478

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Prelude Capital Management's IBER Position: Q2 2022 in Review

Prelude Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q2 2022, closing a stake of 10,000 shares — an estimated $98K sold.

Prelude Capital Management first reported a position in IBER in Q2 2021 and held it in 4 quarters. The position peaked at $133K in Q3 2021. 46 funds tracked by Wall St. Rank hold IBER as of Q2 2022.

  • Prelude Capital Management reported no remaining Ibere Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Prelude Capital Management sold 10,000 Ibere Pharmaceuticals shares in Q2 2022, an estimated $98K.
  • Prelude Capital Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Prelude Capital Management's Ibere Pharmaceuticals position peaked at $133K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.